You are here

  • Home
  • Archive
  • Volume 79, Issue 6
  • Response to: ‘Regarding microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints’ by Liebling

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Regarding microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints’ by Liebling
Free
  1. Akihiro Nakamura1,2,3,4,
  2. Jason S. Rockel1,2,
  3. Mohit Kapoor1,2,5,6
  1. 1 Arthritis Program, University Health Network, Toronto, Ontario, Canada
  2. 2 Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada
  3. 3 Division of Rheumatology, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
  4. 4 Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
  5. 5 Department of Surgery, University of Toronto, Toronto, Ontario, Canada
  6. 6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr. Mohit Kapoor, Arthritis Program, University Health Network, Toronto, Ontario, Canada; mkapoor{at}uhnresearch.ca

https://doi.org/10.1136/annrheumdis-2019-215509

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We wish to thank Dr Liebling for the relevant comments1 regarding our recent article in Annals of the Rheumatic Diseases entitled ‘MicroRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints’.2 We are delighted that our article has gathered such interest in the scientific community and are happy to provide additional comments. In the aforementioned publication, we determined the potential of locked nucleic acid, antisense oligonucleotides against microRNA-181a-5p (LNA-miR-181a-5p ASO) as a therapy for the treatment of osteoarthritis (OA).2 The chemical modification of LNA is one of the most advanced ASO delivery systems. LNA modifications enable design of oligonucleotides that are short while maintaining high affinity and stable binding towards targets. …

    View Full Text

    Linked Articles